Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast.
Phase of Trial: Phase II
Latest Information Update: 17 May 2012
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 12 May 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT00496808).
- 12 May 2009 Planned number of patients changed from 20 to 71 as reported by ClinicalTrials.gov.